Status:
ACTIVE_NOT_RECRUITING
A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma
Lead Sponsor:
Takeda
Conditions:
Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
Participants with CD30-positive lympoma will be treated with brentuximab vedotin according to their clinic's standard practice. The main aim of this study is to collect information on any side effect...
Detailed Description
This is an observational, non-interventional, prospective study in participants with CD30-positive lymphoma who are receiving or will receive the standard treatment of brentuximab vedotin. This study ...
Eligibility Criteria
Inclusion
- Undergoing treatment with brentuximab vedotin (of less than 3 months from initial treatment with brentuximab vedotin) or to be received with brentuximab vedotin.
- CD30-positive lymphoma by INV (any CD30 expression)
Exclusion
- 1\. Who currently participates in or with plan to participate in any interventional clinical trial.
Key Trial Info
Start Date :
June 7 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 19 2026
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04837222
Start Date
June 7 2021
End Date
June 19 2026
Last Update
December 24 2025
Active Locations (32)
Enter a location and click search to find clinical trials sorted by distance.
1
Anhui Provincial Cancer Hospital
Hefei, Anhui, China, 230001
2
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100010
3
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100044
4
Peking University Third Hospita
Beijing, Beijing Municipality, China, 100191